Two weeks ago, the Moderna mRNA vaccine became the third vaccine to be approved for emergency use in the UK. With 94% effectiveness, this vaccine is an exciting addition to the COVID-19 relief effort and brings us one step closer to the end of the pandemic. Before 2020, efforts to study mRNA vaccines weren’t at the forefront of RNA research, however over the next year we could expect to find out just how versatile and effective RNA-based vaccines can really be.
To discuss the effort that has been made throughout 2020 to understand RNA biology and how instrumental this understanding is to anti-infectives drug discovery, attend the RNA Anti-Infectives Symposium taking place on 4 March 2021.
Join Katja Petzold (Karolinska Institute and member of the COVID19-NMR project), Amanda Hargrove (Duke University), and more to take a look at how our understanding of RNA has increased rapidly in order to treat COVID-19 and how this impact will promote drug discovery in the RNA space in years to come.
Make sure to attend if you want to:
- Understand how NMR spectroscopy was used for high-resolution structural characterisation of SARS-CoV-2 structure and how this can be applied to in-cell methodologies for future RNA projects
- Discover how to apply knowledge of RNA biology to alternate pathogens including regulation of gene expression in disease treatment and antibacterials
- Identify how COVID-19 has impacted our understanding of RNA biology and the implications this will have for your drug discovery programme
Enjoy this symposium for free when you book onto the Targeting RNA Congress 2021, or purchase a stand-alone ticket to the symposium for a one-off price of $399. As a reader of Drug Discovery World save an additional 10% when you book your place with code DDW10.
